This is a Validated Antibody Database (VAD) review about dog MAP2K1, based on 15 published articles (read how Labome selects the articles), using MAP2K1 antibody in all methods. It is aimed to help Labome visitors find the most suited MAP2K1 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
MAP2K1 synonym: dual specificity mitogen-activated protein kinase kinase 1; dual specificity mitogen activated protein kinase kinase 1

Santa Cruz Biotechnology
mouse monoclonal (7E10)
  • western blot; human; loading ...; fig 3b
Santa Cruz Biotechnology MAP2K1 antibody (Santa Cruz, sc-81503) was used in western blot on human samples (fig 3b). Int J Oncol (2018) ncbi
mouse monoclonal (9G3)
  • western blot; human; loading ...; fig 6b
Santa Cruz Biotechnology MAP2K1 antibody (Santa Cruz Biotechnology, sc-81504) was used in western blot on human samples (fig 6b). BMC Cancer (2015) ncbi
mouse monoclonal (7E10)
  • western blot; human; loading ...; fig 6b
Santa Cruz Biotechnology MAP2K1 antibody (Santa Cruz Biotechnology, sc-81503) was used in western blot on human samples (fig 6b). BMC Cancer (2015) ncbi
Invitrogen
mouse monoclonal (3D9)
  • proximity ligation assay; human; 1:100; fig 8
In order to elucidate how protein tyrosine phosphatase interacting protein 51 modulates the NF-kappaB signaling pathway, Invitrogen MAP2K1 antibody (Life Technologies, 13-3500) was used in proximity ligation assay on human samples at 1:100 (fig 8). Biomolecules (2015) ncbi
Cell Signaling Technology
rabbit monoclonal (166F8)
  • western blot; mouse; 1:2000; loading ...; fig 8b
  • western blot; human; 1:2000; loading ...; fig 8a
Cell Signaling Technology MAP2K1 antibody (CST, 2338S) was used in western blot on mouse samples at 1:2000 (fig 8b) and in western blot on human samples at 1:2000 (fig 8a). J Cell Sci (2019) ncbi
rabbit monoclonal (166F8)
  • western blot; human; 1:1000; fig 4a
In order to measure the expressions of XCR1 mRNA breast cancer cell lines, Cell Signaling Technology MAP2K1 antibody (Cell Signaling, 2338) was used in western blot on human samples at 1:1000 (fig 4a). Breast Cancer (Dove Med Press) (2017) ncbi
rabbit monoclonal (166F8)
  • immunohistochemistry - paraffin section; mouse; loading ...; fig s1i
Cell Signaling Technology MAP2K1 antibody (Cell Signaling, 2338) was used in immunohistochemistry - paraffin section on mouse samples (fig s1i). Nature (2017) ncbi
rabbit monoclonal (166F8)
  • western blot; human; 1:2000; fig 5e
In order to discuss the role of myeloid cells in pancreatic cancer pathogenesis, Cell Signaling Technology MAP2K1 antibody (cell signalling, 2338) was used in western blot on human samples at 1:2000 (fig 5e). Gut (2017) ncbi
rabbit monoclonal (166F8)
  • western blot; human; loading ...; fig 3b
In order to develop an inducible expression system that allows for streptavidin-hemagglutinin-tag-based interaction studies for tandem affinity purification-mass spectrometry, Cell Signaling Technology MAP2K1 antibody (Cell Signaling, 2338) was used in western blot on human samples (fig 3b). Mol Cell Proteomics (2016) ncbi
rabbit monoclonal (166F8)
  • immunohistochemistry - paraffin section; human
Cell Signaling Technology MAP2K1 antibody (Cell Signalling, 2338) was used in immunohistochemistry - paraffin section on human samples . Cancer Genet (2015) ncbi
rabbit monoclonal (166F8)
  • western blot; mouse; fig s2
In order to investigate metabolic pathways using pancreatic ductal adenocarcinoma cells, Cell Signaling Technology MAP2K1 antibody (Cell Signaling, 2338) was used in western blot on mouse samples (fig s2). Proc Natl Acad Sci U S A (2015) ncbi
rabbit monoclonal (166F8)
  • immunohistochemistry - frozen section; rat; 1:200
  • western blot; rat; 1:1000
Cell Signaling Technology MAP2K1 antibody (Cell Signaling Technology, 2338) was used in immunohistochemistry - frozen section on rat samples at 1:200 and in western blot on rat samples at 1:1000. BMC Complement Altern Med (2014) ncbi
rabbit monoclonal (166F8)
  • western blot; mouse
Cell Signaling Technology MAP2K1 antibody (Cell Signaling Technology, 2338) was used in western blot on mouse samples . J Biol Chem (2014) ncbi
rabbit monoclonal (166F8)
  • immunohistochemistry - paraffin section; human; 1:50
  • western blot; human
In order to evaluate the effect of NVP-BEZ235 and MEK inhibitor ADZ4266 on murine mismatch repair deficient tumors, Cell Signaling Technology MAP2K1 antibody (Cell Signaling Technologies, 2338S) was used in immunohistochemistry - paraffin section on human samples at 1:50 and in western blot on human samples . PLoS ONE (2013) ncbi
rabbit monoclonal (166F8)
  • western blot; human
In order to describe the phenotype of seven patients with de novo deletions of chromosome 19p13.3, Cell Signaling Technology MAP2K1 antibody (Cell Signaling, 2338) was used in western blot on human samples . Clin Genet (2014) ncbi
BD Biosciences
mouse monoclonal (25/MEK1)
  • western blot; human; fig s2
BD Biosciences MAP2K1 antibody (BD Transduction Laboratories, 610121) was used in western blot on human samples (fig s2). Cell Commun Signal (2016) ncbi
Articles Reviewed
  1. Zhang S, Liu W, Yang Y, Sun K, Li S, Xu H, et al. TMEM30A deficiency in endothelial cells impairs cell proliferation and angiogenesis. J Cell Sci. 2019;132: pubmed publisher
  2. Qi Z, Xu H, Zhang S, Xu J, Li S, Gao H, et al. RIPK4/PEBP1 axis promotes pancreatic cancer cell migration and invasion by activating RAF1/MEK/ERK signaling. Int J Oncol. 2018;52:1105-1116 pubmed publisher
  3. Yang X, Qi L, Lin F, Ou Z. The role of the chemokine receptor XCR1 in breast cancer cells. Breast Cancer (Dove Med Press). 2017;9:227-236 pubmed publisher
  4. Genovese G, Carugo A, TEPPER J, Robinson F, Li L, Svelto M, et al. Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Nature. 2017;542:362-366 pubmed publisher
  5. Zhang Y, Velez Delgado A, Mathew E, Li D, Mendez F, Flannagan K, et al. Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer. Gut. 2017;66:124-136 pubmed publisher
  6. Bigenzahn J, Fauster A, Rebsamen M, Kandasamy R, Scorzoni S, Vladimer G, et al. An Inducible Retroviral Expression System for Tandem Affinity Purification Mass-Spectrometry-Based Proteomics Identifies Mixed Lineage Kinase Domain-like Protein (MLKL) as an Heat Shock Protein 90 (HSP90) Client. Mol Cell Proteomics. 2016;15:1139-50 pubmed
  7. Hennig A, Markwart R, Wolff K, Schubert K, Cui Y, Prior I, et al. Feedback activation of neurofibromin terminates growth factor-induced Ras activation. Cell Commun Signal. 2016;14:5 pubmed publisher
  8. Kumarasamy V, Shin Y, White J, Sun D. Selective repression of RET proto-oncogene in medullary thyroid carcinoma by a natural alkaloid berberine. BMC Cancer. 2015;15:599 pubmed publisher
  9. Brobeil A, Kämmerer F, Tag C, Steger K, Gattenlöhner S, Wimmer M. PTPIP51—A New RelA-tionship with the NFκB Signaling Pathway. Biomolecules. 2015;5:485-504 pubmed publisher
  10. Kumar A, Pathak P, Purkait S, Faruq M, Jha P, Mallick S, et al. Oncogenic KIAA1549-BRAF fusion with activation of the MAPK/ERK pathway in pediatric oligodendrogliomas. Cancer Genet. 2015;208:91-5 pubmed publisher
  11. Guillaumond F, Bidaut G, Ouaissi M, Servais S, Gouirand V, Olivares O, et al. Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma. Proc Natl Acad Sci U S A. 2015;112:2473-8 pubmed publisher
  12. Cheng C, Lin J, Su S, Tang N, Kao S, Hsieh C. Electroacupuncture-like stimulation at Baihui and Dazhui acupoints exerts neuroprotective effects through activation of the brain-derived neurotrophic factor-mediated MEK1/2/ERK1/2/p90RSK/bad signaling pathway in mild transient focal cerebral ischemi. BMC Complement Altern Med. 2014;14:92 pubmed publisher
  13. Park E, Kim B, Lee E, Chang E, Kim D, Choi S, et al. Targeting of receptor for advanced glycation end products suppresses cyst growth in polycystic kidney disease. J Biol Chem. 2014;289:9254-62 pubmed publisher
  14. Kucherlapati M, Esfahani S, Habibollahi P, Wang J, Still E, Bronson R, et al. Genotype directed therapy in murine mismatch repair deficient tumors. PLoS ONE. 2013;8:e68817 pubmed publisher
  15. Nowaczyk M, Thompson B, Zeesman S, Moog U, Sanchez Lara P, Magoulas P, et al. Deletion of MAP2K2/MEK2: a novel mechanism for a RASopathy?. Clin Genet. 2014;85:138-46 pubmed publisher